Citius Pharmaceuticals (CTXR) Reiterated at Buy by Dawson James on I/ONTAK Spinoff, $10 Price Target Maintained
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Buy rating and $10.00 price target on Citius Pharmaceuticals (NASDAQ: CTXR), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
